Pirfenidone is an anti fibrotic drug used to treat idiopathic pulmonary fibrosis. It has been approved for marketing in multiple countries and regions around the world, including China, and has been included in the national medical insurance catalog.

Global Listing Status

(1) Japan: First approved for listing in 2008

(2) Europe: Approved by the European Medicines Agency (EMA) in 2011

(3) USA: Approved for market by FDA in 2014

2. Listing situation in China

(1) Approval time: Approved for listing by the National Medical Products Administration in 2011

(2) Product Name: Aisirui

(3) Medical insurance situation: included in the national medical insurance catalog in 2017

3 Basic information of drugs

(1) Drug type: Oral small molecule compound

(2) Pharmacological effects: It has anti fibrotic, anti-inflammatory, and antioxidant effects

(3) Indications: Mainly used for the treatment of idiopathic pulmonary fibrosis (IPF)

4. Domestic generic drug situation

(1) Current situation of generic drugs: There are already generic drugs on the market in China

(2) Purchase suggestion: It is recommended to purchase through formal channels to ensure the quality of the drugs